Understanding Continuous Glucose Monitoring

Continuous Glucose Monitoring (CGM) systems have transformed diabetes management by providing real-time insights into glucose levels. Unlike traditional fingerstick testing, which offers only a snapshot, CGM measures glucose in the interstitial fluid every few minutes, delivering a continuous stream of data. This allows users to see trends, detect patterns, and respond proactively to highs and lows. The technology relies on a small sensor inserted just under the skin, typically on the abdomen or arm, which communicates wirelessly with a receiver or smartphone app.

The key advantage of CGM is the ability to set customizable alerts for urgent low or high glucose events, and many systems now offer predictive alerts that warn of impending fluctuations 20-30 minutes in advance. This feature alone can prevent dangerous hypoglycemic episodes and improve time-in-range dramatically. CGM data also enables healthcare providers to adjust medication regimens remotely, and users can share access with caregivers via cloud-based platforms.

Core Features Compared Across Brands

While all CGM systems share the basic principle of continuous monitoring, the implementation and feature sets vary widely. Understanding these differences is critical when selecting a system.

  • Wear Duration: Sensors last anywhere from 7 days to 90 days, affecting both convenience and cost.
  • Calibration: Some systems require periodic fingerstick calibrations, while others are factory-calibrated.
  • Alert Systems: Basic threshold alerts versus predictive alerts; some offer urgent low soon warnings.
  • Data Sharing: Real-time sharing with up to 10 followers is common, but some limit followers or require manual uploads.
  • Integration: Direct connection to insulin pumps and automated insulin delivery (AID) systems is a major differentiator.
  • Mobile App Experience: App design, data visualization, and ease of use vary significantly.

Leading CGM Brands in Detail

Dexcom: The Accuracy and Integration Leader

Dexcom has long been considered the gold standard for CGM accuracy, with its G6 model achieving a MARD (Mean Absolute Relative Difference) of around 9-10% — among the lowest in the industry. The sensor lasts up to 10 days and requires no fingerstick calibration. The Dexcom G6 transmits real-time glucose readings every 5 minutes to a dedicated receiver or the Dexcom G6 app on iOS and Android.

  • Latest Technology: The Dexcom G7, released in 2022-2023, shrinks the sensor to one-third the size of the G6, reduces warm-up time to 30 minutes (from 2 hours), and extends wear to 10.5 days. It also includes a built-in transmitter, meaning no separate re-usable component.
  • Alert Features: Customizable alerts for high and low thresholds, plus an Urgent Low Soon alert that preemptively warns when glucose is predicted to drop below 55 mg/dL within 20 minutes. The G7 also adds a signal loss alert.
  • Data Sharing: Dexcom Follow app allows up to 10 followers to see glucose data in real time. The Clarity app provides detailed reports and analytics for healthcare providers.
  • Integration: Dexcom sensors integrate directly with the Tandem t:slim X2 and Omnipod 5 insulin pumps, enabling automated insulin delivery without an additional receiver. The G6 and G7 are also compatible with many smartwatches (Apple Watch, Wear OS) for glanceable readings.

Who it suits best: People who want the highest accuracy, pump integration, and rich data sharing. Ideal for those using or planning to use an automated insulin delivery system. The 10-day wear is shorter than some competitors, and the cost is on the higher end.

Abbott FreeStyle Libre: Simplicity and Ease of Use

The FreeStyle Libre line popularized flash glucose monitoring, where users scan the sensor with a reader or smartphone to get a reading. The newer FreeStyle Libre 2 offers optional real-time alerts for high and low glucose, while the FreeStyle Libre 3 features a miniaturized sensor and continuous real-time data transmission comparable to traditional CGM.

  • Sensor Technology: The Libre 3 sensor is the smallest in the world, with a volume of just 0.025 cubic inches. It is factory-calibrated and has a 14-day wear time, the longest among non-implantable sensors. Warm-up is typically 1 hour.
  • Accuracy: The Libre 3 achieves a MARD of approximately 7.9% on the arm, placing it among the most accurate systems. The Libre 2 has a MARD of about 9.2%.
  • App Features: The FreeStyle Libre 3 app provides real-time glucose readings with optional alarms (can set silent or audible). The system also tracks time in range, daily patterns, and generates Ambulatory Glucose Profile (AGP) reports. No separate receiver is needed; the app acts as the primary display.
  • Data Sharing: The LibreLinkUp app allows caregivers to follow remotely. However, the real-time sharing is not as robust as Dexcom's Follow; some users report that sharing can be delayed or requires manual refreshing.
  • Integration: The FreeStyle Libre 3 does not currently integrate directly with insulin pumps for automated insulin delivery, though it can be used with some third-party systems via xDrip and AndroidAPS (open source). Abbott has announced partnerships for future pump integration.

Who it suits best: People who prefer a simple, discrete sensor with long wear and no need for fingerstick calibration. Ideal for those who do not use an insulin pump or want to avoid scanning frequently. The Libre 3's small size is a major advantage for active users.

Medtronic Guardian Connect: Predictive Power and Pump Integration

Medtronic's Guardian Connect system is designed for users of the Medtronic insulin pump ecosystem (MiniMed 670G, 770G, 780G). The sensor uses a transmitter that attaches to a 7-day wear sensor. Calibration requires fingersticks twice daily on some models, though the newer Guardian 4 sensor reduces this to a single calibration at insertion.

  • Predictive Alerts: The Guardian Connect app uses advanced algorithms to predict glucose levels 10-60 minutes ahead. If it detects that glucose will go below or above a threshold, it sends an alert. This gives users more time to act compared to threshold-only alarms.
  • Sensor Accuracy: The Guardian 4 sensor has a MARD of about 8.7% on the abdomen. It is approved for insulin dosing without confirmatory fingersticks (non-adjunctive use) in the U.S.
  • Automated Insulin Delivery: The Guardian 4 sensor integrates with the MiniMed 780G system, which uses SmartGuard technology to automatically adjust basal insulin and correct boluses when glucose is predicted to rise. This is one of the most advanced hybrid closed-loop systems available.
  • Cloud Integration: The CareLink connect platform provides detailed reports and remote monitoring. Up to 5 followers can access data via the CareLink mobile app.

Who it suits best: Current or prospective Medtronic pump users who want a fully integrated closed-loop experience. The 7-day sensor wear is shorter than competitors, and the requirement for calibration may be a drawback for some. However, the predictive alerts and pump automation are powerful.

Eversense: The Long-Term Implantable Option

Eversense, developed by Senseonics, offers a completely unique approach: an implantable sensor that is inserted under the skin in a minor in-office procedure. The sensor lasts up to 180 days (the Eversense E3 model) with a transmitter worn on the skin above it. The transmitter provides real-time data and must be charged daily for 10-15 minutes.

  • Longevity: The Eversense E3 sensor is approved for up to 180 days of wear, drastically reducing the frequency of sensor changes. This is a significant advantage for those who dislike frequent insertions.
  • Accuracy: The Eversense E3 has a MARD of approximately 8.5% when calibrated twice daily. Calibration is required, though the frequency may decrease over time.
  • Feature Set: On-body vibratory alerts on the transmitter itself, plus visual and audio alerts from the smartphone app. The transmitter also features a "smart" mode that only transmits data when the person is away from their phone.
  • App and Sharing: The Eversense app provides glucose data, trends, and reports. Data can be shared with caregivers via the Eversense Connect web platform, but real-time sharing is less seamless than Dexcom or Libre.
  • Insertion Consideration: The sensor requires a small surgical procedure (a 5-minute insertion) by a trained healthcare provider every 90-180 days. Removal is similarly minor. Some users report initial discomfort or a visible bump on the upper arm.

Who it suits best: Those who want the most convenience in terms of sensor changes — only twice a year — and are comfortable with the insertion procedure. Ideal for people with very active lifestyles or who have difficulty with traditional adhesive sensors due to skin reactions. The need for calibration and the requirement to charge the transmitter daily are trade-offs.

Emerging Players: CamAPS FX and Others

Beyond the major brands, newer systems like the CamAPS FX (developed in the UK) and the Dexcom G7 integration with the Ypsomed mylife Loop system show the trend toward tighter integration. Additionally, some regulatory approvals have opened the door for non-prescription CGM options like the Abbott Lingo and Dexcom Stelo for people with prediabetes or general wellness, though these are not designed for intensive insulin therapy.

Accuracy and Reliability: What the Data Shows

Accuracy is critical for making treatment decisions. All major CGM brands now meet the FDA's non-adjunctive use standards, meaning readings can be used for dosing without a fingerstick. However, MARD values vary by sensor generation and body site.

  • Dexcom G6/G7: MARD of 9.0-10.2% on abdomen (G7 slightly better on arm). Consistent performance over 10 days.
  • Abbott FreeStyle Libre 3: MARD of 7.9% on arm — the highest accuracy in clinical trials for a factory-calibrated sensor.
  • Medtronic Guardian 4: MARD of 8.7% on abdomen, with good performance during the 7-day wear.
  • Eversense E3: MARD of 8.5% after calibration, but accuracy may decline toward the end of the 180-day period in some users.

Real-world performance may differ. Factors such as body temperature, pressure on the sensor (compression lows), and user technique can affect accuracy. A 2023 study published in Diabetes Technology & Therapeutics found that the Dexcom G6 and Libre 3 had the lowest rates of sensor failures and the highest user satisfaction scores among 1,200 participants. External link: Read the study.

Cost and Insurance Considerations

Expenses vary depending on insurance coverage, pharmacy benefit managers, and whether the system is considered DME (durable medical equipment) or retail. In general:

  • Dexcom tends to be more expensive per month, but many insurance plans cover it under pharmacy benefits for type 1 diabetes. The G7 sensor costs around $180-200 per box (3 sensors for 30 days), plus transmitter cost (built-in, so no separate cost).
  • FreeStyle Libre 3 is often priced lower, with a retail cost of about $75-100 per month for sensors (2 sensors for 28 days). Abbott also offers a patient assistance program.
  • Medtronic Guardian pricing is often bundled with pump purchases; standalone sensor costs are comparable to Dexcom but may require separate transmitter purchase.
  • Eversense costs include the insertion procedure (covered by many insurance plans), sensor (around $1,500 for 180-day sensor, plus transmitter), and recurring calibration strips.

Many insurance plans cover CGM for type 1 diabetes and some for type 2 diabetes on insulin. Medicare covers all major brands for eligible beneficiaries. For out-of-pocket estimates, check manufacturer savings programs: Dexcom cost info, Abbott savings.

User Experience: What People Actually Say

User forums and surveys reveal consistent themes:

  • Dexcom users love the reliability of alerts and the seamless integration with pumps. The 10-day sensor is a minor inconvenience; some wish it lasted longer. Skin irritation from the adhesive is a common issue.
  • FreeStyle Libre users praise the simplicity and the long 14-day wear. The lack of pump integration is a drawback for those wanting closed-loop. Some report occasional sensor failures or inaccurate readings in the first 24 hours.
  • Medtronic Guardian users appreciate the predictive alerts and loop integration but dislike the calibration requirement and shorter sensor life. The transmitter battery must be replaced every 12 months.
  • Eversense users highlight the freedom from frequent sensor changes and the vibratory alerts. However, the need to charge the transmitter daily and the insertion procedure are common complaints.

Online communities like the CGM subreddit and Facebook groups can provide real-world perspectives, but always consult your healthcare provider before choosing a system.

Integration with Automated Insulin Delivery Systems

This is a major differentiator. Currently:

  • Dexcom G6/G7 are the only sensors that work with the Tandem Control-IQ and Omnipod 5 systems, the two most widely used AID systems in the U.S. The G6 also works with DIY systems like Loop.
  • Medtronic Guardian is the only sensor that works with the MiniMed 780G, offering a fully integrated closed-loop experience (with the trade-off of calibration).
  • FreeStyle Libre 3 is not yet compatible with any approved AID system in the U.S., though integration with the Ypsomed mylife Loop is approved in Europe. Open-source solutions (AndroidAPS) can connect the Libre 3 via third-party bridges.
  • Eversense does not have pump integration and is not expected to soon.

If you plan to use an automated insulin delivery system, the choice of CGM will largely dictate your pump options. For those on multiple daily injections, any CGM can work, but integration with smart pens (e.g., InPen) is also emerging.

Several innovations are on the horizon:

  • Multi-hour predictive alerts using artificial intelligence – Medtronic is developing a system that predicts glucose trends up to 4 hours ahead.
  • Non-invasive glucose monitoring via optical sensors or sweat analysis, though still years from market.
  • Smaller, longer-lasting sensors – both Dexcom and Abbott are working on 14-15 day sensors with even smaller profiles.
  • Over-the-counter (OTC) CGM for non-diabetic use – Dexcom Stelo and Abbott Lingo are already approved, but their value for diabetes management with insulin is limited.
  • Dual hormone closed-loop systems combining insulin and glucagon – Beta Bionics iLet is an example, but requires a compatible CGM.

These developments promise to make CGM more accessible and even more seamlessly integrated into daily life.

Making Your Decision: A Quick Checklist

Before choosing a CGM, ask yourself:

  1. Do I use an insulin pump? If yes, which brand? (Dexcom for Omnipod/Tandem; Medtronic for MiniMed)
  2. How important is sensor wear time? (If you dislike frequent changes, Eversense or Libre 3 may be best.)
  3. Do I want to avoid fingerstick calibration? (Factory-calibrated: Dexcom G6/G7, Libra 3; calibration needed: Medtronic, Eversense.)
  4. How important are advanced alerts? (Predictive alerts: Dexcom G7, Medtronic Guardian; basic thresholds: Libre 2/3.)
  5. What is my budget after insurance? (Libre 3 is typically cheapest; Eversense may have higher upfront cost but long-term savings.)
  6. Do I need real-time data sharing with family? (Dexcom Follow is the gold standard; LibreLinkUp is good; Medtronic CareLink is adequate.)

No single CGM is best for everyone. The right choice balances accuracy, wear time, integration, and lifestyle. Many healthcare providers can start you on a trial sensor or a low-cost starter kit (e.g., Dexcom introductory offer) so you can experience the system firsthand.

Final Thoughts

Continuous Glucose Monitoring is no longer a luxury — it is a standard of care for people with diabetes taking insulin, and increasingly for those with type 2 not on intensive therapy. By understanding the features, costs, and limitations of each brand, you can make an informed decision that improves your glucose control and quality of life. Advances in sensor accuracy, longer wear periods, and tighter pump integration will continue to drive the market forward. Keep current with FDA approvals and new product launches; for the latest updates, follow the official channels of each manufacturer or consult a resource like the American Diabetes Association's CGM guide.